AMPLIFICATION AND OVEREXPRESSION OF THE PSMB5 GENE CONTRIBUTE TO BORTEZOMIB RESISTANCE IN RE-TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

被引：0
|
作者：
Altavilla, Giuseppe [1 ]
Arrigo, Carmela [1 ]
Sauta, Maria Grazia [1 ]
Galletti, Giuseppe [1 ]
Gnani, Alessandro [1 ]
Pettineo, Giuseppe [1 ]
Buemi, Barbara [1 ]
Pitini, Vincenzo [1 ]
机构：
[1] Univ Messina, Human Pathol Dpt, Med Oncol Unit, I-98100 Messina, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 43 条
  • [1] Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma
    Altavilla, G.
    Arrigo, C.
    Marabello, G.
    Galletti, G.
    Santarpia, M.
    Sauta, M.
    Pitini, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
    Oerlemans, Ruud
    Franke, Niels E.
    Assaraf, Yehuda G.
    Cloos, Jacqueline
    van Zantwijk, Ina
    Berkers, Celia R.
    Scheffer, George L.
    Debipersad, Kabir
    Vojtekova, Katharina
    Lemos, Clara
    van der Heijden, Joost W.
    Ylstra, Bauke
    Peters, Godefridus J.
    Kaspers, Gertjan L.
    Dijkmans, Ben A. C.
    Scheper, Rik J.
    Jansen, Gerrit
    BLOOD, 2008, 112 (06) : 2489 - 2499
  • [3] Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen
    Lu Shuqing
    Yang Jianmin
    Huang Chongmei
    Cheng Hui
    Wang, Jianmin
    EXPERIMENTAL HEMATOLOGY, 2011, 39 (12) : 1117 - 1118
  • [4] Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib
    Barrio, Santiago
    Stuhmer, Thorsten
    Teufel, Eva
    Barrio-Garcia, Clara
    Chatterjee, Manik
    Schreder, Martin
    Das Gupta, Mithun
    Rosenwald, Andreas
    Tibes, Raoul
    Braggio, Esteban
    Stewart, A. Keith
    Bargou, Ralf C.
    Einsele, Hermann
    Kortum, K. Martin
    BLOOD, 2016, 128 (22)
  • [5] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
    Allmeroth, Kira
    Horn, Moritz
    Kroef, Virginia
    Miethe, Stephan
    Mueller, Roman-Ulrich
    Denzel, Martin S.
    LEUKEMIA, 2021, 35 (03) : 887 - 892
  • [6] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
    Kira Allmeroth
    Moritz Horn
    Virginia Kroef
    Stephan Miethe
    Roman-Ulrich Müller
    Martin S. Denzel
    Leukemia, 2021, 35 : 887 - 892
  • [7] Feasibility and efficacy of bortezomib re-treatment in multiple myeloma
    Ciolli, S.
    Leoni, E.
    Casini, C.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 95 - 95
  • [8] No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib
    Politou, M
    Karadimitris, A
    Terpos, E
    Kotsianidis, I
    Apperley, JF
    Rahemtulla, A
    LEUKEMIA RESEARCH, 2006, 30 (02) : 240 - 241
  • [9] RESPONSE TO RE-TREATMENT ON RELAPSE MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH BORTEZOMIB
    Rubio-Martinez, A.
    Recasens, V.
    Soria, B.
    Montanes, M. A.
    Rubio-Escuin, R.
    Giraldo, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 261 - 261
  • [10] Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma
    Knopf, Kevin B.
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Gravel, Jonathan
    Lefebvre, Patrick
    Niculescu, Liviu
    Ba-Mancini, Abbie
    Ma, Esprit
    Shi, Hongliang
    Comenzo, Raymond L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 380 - 388
12345